Cookies on our website

We use cookies on our website. To learn more about cookies, how we use them on our site and how to change your cookie settings please view our cookie policy. By continuing to use this site without changing your settings you consent to our use of cookies in accordance with our cookie policy.

Read more Close
Skip Ribbon Commands
Skip to main content
Sign In

News

A&O advises Grünenthal on USD922 million deal with AstraZeneca for Nexium and Vimovo

 

30 October 2018

Allen & Overy has advised science-based pharmaceutical company Grünenthal on its acquisition of AstraZeneca’s European rights to prescription Nexium and the global (excluding the US and Japan) rights to Vimovo for a total maximum consideration of USD922 million, including milestones. The transaction marks the single biggest investment in Grünenthal’s history, significantly strengthening the company’s position as a worldwide leader in innovative pain management and related therapies.

The A&O team was led by corporate M&A partner Matthew Appleton, with corporate partner Nigel Parker advising on commercial/IP aspects of the transactions. Counsel Thomas Masterman provided antitrust advice. Partner Ken Coleman provided U.S. related advice and German partner Heike Weber advised on tax aspects.

Grünenthal’s team was led by Sebastian Köhler, General Counsel, together with in-house counsel Claudia Schmidt and Sabine Kruth.

Matthew Appleton comments: “We were delighted to work hand in hand with Grünenthal’s dynamic and commercially-focused legal team to deliver this transformational deal successfully.”

The transaction is subject to approval from relevant antitrust authorities, with closing expected in December 2018. 

For further information, please contact Elizabeth Randall, Elizabeth.Randall@allenovery.com on +44 (0)20 3088 2989.​​​

 

Authors

 

News search




Related people

​Related expertise




  • Add comment (optional)